This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
Protocol Amendment History
15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2025-05-08; most recent amendment 2026-04-22.
Status change: Not Yet Recruiting → Recruiting2025-07-03